World's tallest statue of Lord Ram to be built in Ayodhya

Agencies
November 25, 2018

Lucknow, Nov 25: In order to pacify the saints demanding immediate construction of Ram Temple at Ayodhya, the Yogi Adityanath government in Uttar Pradesh, on the eve of the proposed Dharam Sabha of VHP at Ayodhya, has unveiled a proposal to construct a 221 meter tall Lord Ram statue near the banks of Saryu river in the temple city.

The announcement was made by the CM on Saturday night in the state capital after finalising the details of the construction following presentation by five companies.

Additional chief secretary (Information) Avnish Awasthi said here on Sunday that while the height of the Ram statue would be 151 metres, its overhead umbrella would be 20 metres while the pedestal would be 50 metres.

He said the statue will be made of bronze.

Mr Awasthi said there will be a provision for a “modern museum” inside the base that will showcase the history of Ayodhya and the entire “Ikshvaku Vansh” right from King Manu to the present status of “Ram Janmabhoomi”.

Comments

Ashii
 - 
Sunday, 25 Nov 2018

INDIA is world's largest..

 

Democracy?

MOBocracy?

Statuecracy?

please decide..

fairman
 - 
Sunday, 25 Nov 2018

Wasting the public money.

Instead of statue in the name Shri Ram, Use it for poor in that name.

 

Make good projects for poor,  schools or hospitals for welfare. put the name of the project in Ram.

 

May God good give good wisdom

 

rama
 - 
Sunday, 25 Nov 2018

great going yogi, no problem if small child die who care they are modern slaves, i and my chelas are happy.

 

we will only build statu, statu rest no care

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 30,2020

New Delhi, Jan 30: In a major shift of strategy ahead of the Delhi assembly polls, the Bharatiya Janata Party (BJP) has decided to rope in its senior leaders for massive public rallies.

Its star campaigners like Prime Minister Narendra Modi, Union Home Minister Amit Shah, BJP chief JP Nadda, Uttar Pradesh Chief Minister Yogi Adityanath, and other union ministers would now be addressing massive public rallies in addition to ongoing neighbourhood meetings.

"The big rallies would begin from February 1. While 'Nukkad' meetings will take place till the last day of campaigning, there would be big rallies of the top leadership of the party, " informed a senior party leader.

Sources said the BJP has changed its strategy after the success of its grassroots contact programme as the party wants to consolidate its gains.

"As part of the reworked strategy the BJP has asked its various Mandals to organise public meetings of 10,000-15,000 people in each assembly segment to reach out to the masses," sources added.

While there are two planned for Prime Minister Modi, two have been planned for JDU chief and Bihar Chief Minister Nitish Kumar along with Nadda and Amit Shah. Yogi Aadityanath too would be addressing 12 rallies.

The party is leaving no stone unturned to secure massive gains, which it feels can be converted to victory in the forthcoming polls.

Party sources feel that the relentless campaigning under the guidance of Amit Shah and Nadda has ensured that the morale of party cadre is at an all-time high.

"The neighbourhood meetings have ensured that we have been able to make the people of Delhi aware of the lack of work under the Arvind Kejriwal led Aam Aadmi Party government. They have also been apprised about the anti-national views of the opponents and we think that this is expected to turn the polls into our favour," sources added.

Delhi is scheduled for assembly polls on February 8 and the results for the 70 constituencies will be declared on February 11.

As part of the new strategy, senior leaders like JP Nadda, Amit Shah, Uttar Pradesh chief minister Yogi Adityanath, ministers like Rajnath Singh and Smriti Irani would be holding public rallies in various parts of the city. Several other chief ministers from various BJP ruled states are also expected to be roped in for the campaign.

The strategy for reach out to the masses is an attempt at weakening the hold of AAP on Delhi. With positive feedback coming after the success of the neighbourhood meetings in the past week, the BJP is now looking to increase its potential reach with polls just days away.

Till now the party had deployed 70 union ministers to hold at least one public meeting and one 'padayatra' each as part of the campaign.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 23,2020

New Delhi, Jun 23: "Coming up with a clinically tested, evidence-based medicine was a challenge," said Yoga Guru Ramdev as on Tuesday he launched Patanjali's Coronil tablet, which he claims is a cure for COVID-19. He also talked about various other immunity boosters at an event here during the launch.

Patanjali claims those administered the medicine were fully cured and none died. Ramdev even claimed that 69 per cent of them recovered within 3 days.

"We appointed a team of scientists after COVID-19 outbreak," said Balkrishna, Ramdev's close aide and MD of Patanjali Ayurved. He added that Patanjali conducted a clinical case study on hundreds of positive patients.

Patanjali has claimed that the clinical trials which were controlled in nature, was jointly conducted by Patanjali Research Institute which is based out of Haridwar and the National Institute of Medical Sciences, Jaipur.

Talking about the clinical trials, Ramdev said, "Under this 280 patients were included and 100 per cent of those recovered." He added they were able to control Coronavirus and its complications.

He said that in the next few days, data of the trail will be released as evidence to bolster claims. There are now over 9 million people affected by the pandemic since it broke out in China's Wuhan city in December 2019.

He said Ayurvedic elements are being used in the tablet. "There are more than 100 compounds used in the Coronil," he added. An entire kit is being made for that which consists of other Ayurvedic medicine as well which helps in immunity. The entire kit comes at Rs 600. However, he claimed that it will be given for free to those living below the poverty line.

As for doses, Panajali prescribes: "2-2 tablets should be consumed with hot water half an hour after meals. The above mentioned drug intake and quantity is suitable for people between 15 to 80 years of age. Half the amount of the above mentioned medicines can be used for children between the age of 6 to 14 years." These are the written instructions on the pack.

India has been battling the pandemic with close to 4 lakh cases in India on Tuesday and around 14,000 deaths so far.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.